Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Positive opinions based on significant survival benefit
The Halol facility was placed under Import Alert by USFDA.
Subscribe To Our Newsletter & Stay Updated